Effects of Interleukin-12 on the Induction of Cytotoxic T Lymphocytes from the Regional Lymph Node Lymphocytes of Patients with Lung Adenocarcinoma

Lung cancer-specific cytotoxic T lymphocytes (CTL) were induced by repeated stimulations of regional lymph node lymphocytes (RLNL) in lung cancer patients with either autologous or HLA-A-locus-matched tumor cells. To investigate the effect of interleukin-12 (IL-12), IL-12 was added during the stimulation of RLNL from HLA A24 / adenocarcinoma patients with either autologous tumor cells or HLA A24-positive adenocarcinoma cells (PC-9) in combination with, or instead of interleukin-2 (IL-2), and then the cytotoxic activity, cytokine production and populations of the lymphocyte subsets were examined. The addition of IL-12, or the substitution of IL-2 by IL-12 was found to enhance the cytotoxic activity and the cytokine production (IFN-γ, GM-CSF) of the CTL as compared with IL-2 alone. The cytotoxic activity and cytokine production were both partially inhibited by anti-MHC-class I monoclonal antibody. The CTL thus induced by IL-12 had a higher proportion of CD3⁺/CD56⁺ cells than the CTL induced with IL-2 alone. The positively selected CD8⁺/CD56^– lymphocytes showed PC-9-specific cytotoxic activity, because the population did not show any cytotoxicity to K562 or A549 (HLA-A26/A30). However, the CD3⁺/CD56⁺ lymphocytes were cytotoxic to both PC-9 and K562. In conclusion, IL-12 is considered to be a useful cytokine for both the induction of lung-cancer specific CTL and the augmentation of non-MHC-restricted cytotoxicity against tumor cells, and may be applicable for adoptive immunotherapy using CTL.     

Supraventricular arrhythmia: A complication of 5-fluorouracil therapy

5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens. Gastrointestinal toxicity and myelosuppression are the most common adverse reactions, but, of late, clinical cardiotoxicity has been reported in both prospective and retrospective studies. We present our experience of clinical cardiotoxicity in five patients.     

放疗联合化疗治疗复发直肠癌的临床研究

目的探讨放疗联合化疗治疗复发直肠癌的临床效果。方法对２９例根治术后复发的直肠癌进行了放射治疗，其中１６例同时给予大剂量醛氢叶酸（ＣＦ），氟脲嘧啶（５ＦＵ）的全身化疗（观察组），１３例为单纯放疗（对照组）。结果观察组中局部症状缓解率较对照组高，两组有效率分别为８１．２５％、４６．１６％，有显著性差异（Ｐ＜０．０５），完全缓解分别为１８．７５％、７．６９％。两组放疗引起的局部毒性反应相似。结论ＣＦ／５Ｆｕ配合放射治疗复发直肠癌可提高近期疗效，尤其对于伴远外转移患者为理想、安全的治疗手段。     

桂枝汤有效部位A对体温双向调节作用及其机理研究————对下丘脑NE、DA、5-HT含量的影响

在酵母诱导的发热大鼠中，桂枝汤有效部位Ａ（Ｆｒ．Ａ）能降低下丘脑５－ＨＴ、ＮＥ、ＤＡ含量；在安痛定诱导的低体温大鼠中，能升高５－ＨＴ含量。结果提示，Ｆｒ．Ａ为桂枝汤体温双向调节作用的一种物质基础，影响中枢神经递质５－ＨＴ的水平是其机理之一；其解热作用与影响中枢神经递质ＮＥ和ＤＡ的含量有关     

毛穗藜芦中茋类化合物的化学研究

目的：对毛穗藜芦根茎进行化学成分研究。方法：采用柱层析和薄层层析法进行分离，用ＵＶ，ＩＲ，ＭＳ，１ＨＮＭＲ等光谱技术鉴定化合物的结构。结果：得到２个类化合物，为白藜芦醇和２，３′，４，５′四羟基。结论：为首次从该植物中分离得到     

腺病毒介导的大肠杆菌CD自杀基因体内外对肿瘤杀伤作用的研究

编委会 Editorial Board名誉主编 Honorary Editor-in-chief吴孟超 Wu Meng chao(Second Military Medical University,Shanghai 200433学术顾问 Academic Advisers巴德年 Ba Denian(Chinese Academy of Medical Sciences,Beijing 100730)刘新垣 Liu Xinyuan(Shanghai Institute of Biochemistry,Chinese Academy of Sciences,Shanghai 200031)吴旻 WuMin(Cancer Institute,Chinese Academy of Medical Sciences,Beijing 100021)汤钊猷 Tang Zhaoyou(Shanghai Medical University,Shanghai 200032)主编 Editor-in-chief张友会 Zhang Youhui(Cancer Institute,Chinese Academy of Medical Sciences,Beijing,100021)副主编 Associate Editor-in-chief崔正言 Cul Zhenyan(Department of Immunology,Shandong Academy of Medical Sciences,Jinan 250001)钱振超 Qian Zhenchao(Department of Patho-physiology,Dalian Medical University,Dalian 116027)何球藻 He Qiuzao(Department of Immunology,Shanghai Medical University,Shanghai 200032)董志伟 Dong Zhiwei(Cancer Institute,Chinese Academy of Medical Sciences,Beijing 100021)常务副主编 Managing Editor-in-chief     

肺癌生存5年以上72例分析

[目的]探讨影响肺癌长期生存的因素。方法对1983年1月至1992年12月间收治的经病理证实的存活5年以上的72例肺癌患者进行分析。放疗采用60Co－r线或10MV－X线，大野前后对穿照射Dr40Gy/20次，共4周后缩野加量至总DT52G6y-76Gy（平均61．6Gy，非手术者）或50Gy－70Cy（平均56．1Gy，手术者）。手术均为肺叶（段）切除术。化疗主要方案为（CTX＋5－FU＋VCR、CTX＋ADM＋DDP、CTX＋5－FU＋CBP／E－ADM＋VP-16等。[结果]临床分期、病理类型和是否加用手术治疗对5年生存率的影响，分析显示有统计学差异。I、II、III、IV期5年生存率分别为42．9％、12．9％、5．8％及0；小细胞未分化癌与非小细胞癌的5年生存率分别为3．2％和96％；手术加放疗（加或不加化疗）与放疗（加或不加化疗）的5年生存率分别为对．5％和5．5％。而放疗剂量及是否加化疗对5年生存率的影响未显示有统计学差异。[结论]肺癌应进行早期诊断、早期治疗，尽量采取以手术为主的综合治疗，以提高远期生存率。     

羊红膻中新化合物──羊红膻醇的分离和鉴定

从陕西草药羊红膻Pimpinellathellungiana全草的正丁醇部分分得一个环乙烯类化合物（Ⅰ）和一个环乙醇类化合物（Ⅱ），经化学及光谱分析鉴定Ⅰ为3，4，5－trihydroxy－1－cyclohexene－1－carboxylicacid，即莽草酸（shikimicacid），Ⅱ为1－butyl－3，4，5－trihydroxy－cyclohexanol。Ⅰ为从该植物中首次得到，Ⅱ为一新化合物，定名为羊红膻醇（thellungianol）。     

5-Fu和α干扰素抗肿瘤血管形成协同效应的实验研究

肿瘤化疗常用的细胞毒药物对肿瘤细胞选择性较差,对正常组织造成一定损伤,有时损伤严重而不得不停止化疗.近年来研究表明,一些化疗药物,如环磷酰胺、长春碱类等具有抑制肿瘤血管作用,为改变化疗药物的临床使用方法、降低毒副反应提供了理论依据.5-Fu是常用的化疗药,可长期口服给药,其是否有抗血管形成作用目前国内外尚未见报道;α干扰素的抗肿瘤效应及抗血管形成作用已为人们公认.本实验研究这两种药物是否具有抗肿瘤血管形成的协同效应,以期为两者联合应用提供依据.     

自杀基因联合放射对食管癌细胞株的实验研究

目的自杀基因具有能将无细胞毒性的前体药物转化为有细胞毒性作用的药物而使细胞死亡,通过观察大肠杆菌胞嘧啶脱氨酶/氟胞嘧啶(CD/5-FC)自杀基因系统对食管癌EC109细胞杀伤效应及与放射联合应用对食管癌肿瘤细胞协同杀伤效应。方法采用PCR方法从大肠杆菌基因组DNA中扩增出CD基因;构建重组真核载体pcDNA3.1-CD;用脂质体转染法转染EC109细胞;观察CD/5-FC体系对EC109细胞的杀伤效应和旁观者效应及对放射的增敏效应。结果RT-PCR分析结果表明CD基因已转入EC109细胞并表达。离体实验证实5-FC对转CD基因后的食管癌细胞株有明显的细胞毒作用,含5%的转基因食管癌细胞加入5-FC后的细胞存活比率为41.8%±14.2%,低于对照组的94.6%±4.3%结果(t=3.14,P<0.05);加入10%的转基因细胞的存活比率为37.8%±4.4%,低于对照组的95.6%±5.4%结果(t=9.75,P<0.01)。CD/5-FC体系对肿瘤细胞放射增敏效果明显,加前药5-FC及放射组细胞存活曲线低于单纯加前药5-FC对照组或单纯放射对照组,重复测量数据方差分析结果显示F=11.50,P<0.01;治疗组分别与5-FC对照组及单纯放射对照组相比F值分别为4.11、10.53,P值分别<0.05、0.01。结论CD/5-FC体系的旁观者效应和放射增敏效果明显。